Resources & Evidence Contact us

Turning to nutrition to help address the complications of prematurity

Since 2012, the American Academy of Pediatrics has recommended human milk as the primary source of nutrition for preterm infants, with appropriate fortification for those born weighing <1500 g.1 Fortification with human milk–based fortifiers is the only way to ensure these medically fragile infants receive an exclusive human milk diet (EHMD).

Prolacta products used as a part of that EHMD,2 as compared to cow milk–based fortifiers, have been shown in clinical studies to benefit critically ill, premature infants in the NICU weighing ≤1250 g at birth in many ways including to:

  • Improve health outcomes3,4,5,6,7,8
  • Achieve adequate growth9,10,11
  • Reduce hospital costs6,12

Getting the most out of an EHMD

Clinical value

Learn about cost savings, complication reductions, and health outcomes associated with our products

Clinical evidence

Read peer-reviewed studies and clinical results

Peer support

Gain insights from fellow neonatologists, nurses, and dietitians

Leading the human milk industry in quality and safety


First and only pharmaceutical-grade manufacturing facilities for the testing and processing of human milk


Exceed food-product industry requirements by following stringent quality and safety standards based on those for the human plasma and blood industry in the US

FDA-regulated lab processes

Our human milk laboratory and manufacturing processes are regulated by the U.S. Food and Drug Administration (FDA).

All Prolacta nutritional products are pasteurized to ensure the highest quality and safety, using time and temperature profiles defined by the FDA in its Pasteurized Milk Ordinance (PMO) to destroy pathogenic viruses and bacteria.

While there are other pasteurization and sterilization processes used in the human milk banking industry, only products manufactured with our pasteurization process are clinically shown to improve health and reduce complications when used as part of an EHMD in the neonatal intensive care unit (NICU). There is no clinical data showing similar results using products processed by any other method.

Benefits of HMOs

Prolacta’s 100% human milk–based nutritional products contain a wide spectrum of human milk oligosaccharides (HMOs).13 The immunity, prebiotic, and gut maturation benefits that HMOs promote may have a role in the health outcomes attributed to an EHMD, including Prolacta’s products.14

To learn more

Improving health outcomes for premature infants

For more than two decades, we have been advancing the science of human milk to improve the health of premature, critically ill infants worldwide.

  • The clinical benefits of our products have been demonstrated in 20+ clinical trials studying 5000+ infants
  • Globally, more than 90,000 premature infants have benefited from our proven human milk–based nutritional products*

A cost-effective solution

When used as part of an EHMD, our nutritional products are clinically proven to increase survival and reduce the overall cost of care compared to cow milk–based fortifiers or preterm formula in extremely premature infants.5,6

Tell us how we can help

Clinician-to-clinician guidance

Coding, billing, and reimbursement questions

Finding my sales representative

Support with an order

*Estimated number of premature infants fed Prolacta’s products from January 2007 to December 2022; data on file.